Robert Spiera
Rheumatology · New York, NYNPI 1215031521
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $113,444 of the $149,311 with a category attached, or 76.0%. It is spread thinly across 17 manufacturers, the largest accounting for just 16.2%. Reporting peaked in 2023 at $44,462 and has fallen 77.4% since, to $10,042 in 2025. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $1659.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$24K
- GSK$22K
- Sanofi$19K
- AstraZeneca$18K
- Amgen$14K
- AbbVie$10K
- plus $42K from 11 others
Across 152 payments — averaging $27,296 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$3.3M
- Amgen$193K
- Novartis$154K
- Genentech, Inc.$122K
- AstraZeneca$78K
- Kadmon Corporation LLC$76K
- plus $196K from 8 others
What the payments were for
- Consulting fees$113,44476%
- Speaking & faculty fees$24,84417%
- Travel & lodging$10,2517%
- Food & beverage$7541%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 13 | $24,153 |
| GSK | 7 | $21,953 |
| Sanofi | 7 | $19,386 |
| AstraZeneca | 15 | $18,167 |
| Amgen | 7 | $14,022 |
| AbbVie | 8 | $9,901 |
| Boehringer Ingelheim | 6 | $8,511 |
| Galderma Laboratories, L.p. | 2 | $6,795 |
| E.r. Squibb & Sons, L.L.C. | 2 | $6,300 |
| Boehringer Ingelheim International GmbH | 7 | $5,585 |
| Actelion Pharmaceuticals US, Inc. | 7 | $5,303 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $3,600 |
| Sanofi US Services Inc. | 1 | $2,579 |
| Regeneron | 4 | $2,028 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 1 | $900 |
| Novartis | 1 | $110 |
| United Therapeutics Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,311 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 64 | $748,616 |
| Enbrel SureclickEtanercept | 78 | $614,115 |
| EnbrelEtanercept | 29 | $356,762 |
| RinvoqUpadacitinib | 34 | $208,267 |
| Xeljanz XrTofacitinib Citrate | 15 | $81,297 |
| ThalomidThalidomide | 11 | $51,340 |
| Actemra ActpenTocilizumab | 18 | $21,266 |
| RidauraAuranofin | 12 | $17,665 |
| RasuvoMethotrexate/Pf | 11 | $9,453 |
| Colchicine | 60 | $6,525 |
| Cevimeline Hcl | 26 | $5,849 |
| Mycophenolate Mofetil | 32 | $5,741 |
| Hydroxychloroquine Sulfate | 173 | $5,681 |
| MethotrexateMethotrexate Sodium | 194 | $4,775 |
| Febuxostat | 14 | $2,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $14,022 | $356,76229 claims |
| AbbVieRinvoq | $9,901 | $208,26734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 541 rheumatology providers in New York.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.